Lincoln Pharmaceuticals Ltd. Share Price

Overview

Lincoln Pharmaceuticals Ltd. share price is currently ₹544.66, up by ₹0.84 (0.15%) from its previous closing price of ₹543.82. The share price has declined -11% over the past month and gained 4.67% over the past year. The stock's 52-week low and high are ₹436.66 and ₹758.14, respectively. Lincoln Pharmaceuticals Ltd. has a market capitalisation of ₹ 1,120.00 Cr. The share price was last updated on 14 Oct 2026, 03:30 PM IST.

Lincoln Pharmaceuticals Ltd.
Lincoln Pharmaceuticals Ltd.
LINCOLN
 ₹0.00
 ₹0.84
0.15%
Healthcare
 ₹0.00(%)1D

Updated: 14 Oct 2026, 03:30:01 pm IST

Market Data

Open Price

 ₹539.35

Prev. Close

 ₹543.82
 ₹536.64

Day Low

 ₹544.66

Day High

 ₹436.66

52 Week Low

 ₹758.14

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryMicro Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

11.31

Sector PE

42.81

PB Ratio

1.44

Sector PB

5.66

EPS

48.15

Dividend Yield

0.32

Today's Volume

19.702 K

5 Day Avg. Volume

24.434 K

PEG Ratio

1.68

Market Cap.

₹ 1,120.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 18% at ₹1.8/Share
11-Sep-202611-Sep-2026
DividendsFinal Dividend of 18% at ₹1.8/Share
12-Sep-202512-Sep-2025
DividendsFinal Dividend of 18% at ₹1.8/Share
13-Sep-202414-Sep-2024

Mutual Fund Ownership

Mutual Fund Holder
Aug 26
Shares held
Sep 26
Shares held
Motilal Oswal BSE Healthcare ETF264
268
(1.52%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth124
126
(1.61%)

About Lincoln Pharmaceuticals Ltd. 👋

Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading pharmaceutical products, as well as undertaking contract manufacturing from pharmaceuticals companies across India and the globe. The Company's product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, SVP injectables, dry-powder suspensions, liquid injection, and pharma products. It offers products for anti-infective, respiratory system, gynecology, cardio and CNS (central nervous system), antibacterial, dermatological infection, anti-diabetic, and anti-malaria. The Company is also engaged in building a portfolio of lifestyle and chronic segments, primarily in women's healthcare and dermatology. The Company caters to approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia, and 26 states across India. The Company has two manufacturing facilities located in Mehsana and Khatraj, Gujarat.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
CA Omkar Bhutada - SEBI Reg IA

CA Omkar Bhutada - SEBI Reg IA

29 Apr • 3:30 PM · SEBI-Registered Analyst

Strong post-accumulation breakout, but structurally a bit more explosive

LINCOLN
What stands out here: Extended sideways movement after a sharp prior decline Clear absorption phase near the lows (₹450–₹500 zone) Gradual tightening before expansion Now we see a vertical breakout candle straight through ₹700 resistance. What Makes This Setup Powerful 1. Violent Expansion from Base Unlike slow breakouts, this is a range expansion + momentum ignition: Large bullish candle (~18–19%) Closing near highs No supply visible near breakout This typically signals: Strong institutional participation Possible news or earnings trigger (common in pharma) 2. V-Shape Recovery + Breakout Price didn’t grind slowly. It: Reversed sharply from ₹450 Built a mini base Then exploded This pattern often leads to fast trending legs, not slow moves. 3. Clean Supply Removal The ₹680–₹700 zone was supply earlier. Now: Completely taken out in one move Sellers trapped immediately Measured Move Projection Range height: ₹700 – ₹460 ≈ ₹240 Breakout zone: ₹700 Projected move: ₹900–₹950 potential (swing basis) Your arrow towards ₹820–₹850 is conservative and realistic for first leg.

See More
Rajneesh Sharma CFTe

Rajneesh Sharma CFTe

12 Feb • 5:30 PM · SEBI-Registered Analyst

Lincoln Pharmaceuticals Ltd (Weekly Chart): Descending Channel Breakout Near ₹615 Resistance with RSI Momentum Shift

LINCOLN
📌 Lincoln Pharmaceuticals Ltd (Weekly Chart): Descending Channel Breakout Near ₹615 Resistance with RSI Momentum Shift 🔍 Technical Analysis 1. Price Structure The stock moved from a strong prior uptrend into a prolonged corrective phase, forming a sequence of lower highs. Recent price action shows a sharp bullish candle emerging from the lower end of the range, indicating strong reaction from lower levels. 2. Trendlines & Structure Price had been moving within a short-term falling channel after the decline from higher levels. The latest weekly candle shows price pushing toward the upper boundary of this structure, suggesting a structural shift from contraction toward expansion. 3. Key Levels (Chart Observations) Immediate Resistance Zone: ₹615–₹620 area where price is currently reacting. Intermediate Level: ₹604–₹605 acting as a horizontal pivot seen multiple times on the chart. Major Overhead Resistance: Around ₹689, aligned with prior swing highs. Rising Support: Long-term ascending trendline visible below current price structure. 4. Momentum (RSI) Weekly RSI has rebounded sharply from lower levels, moving toward higher territory. The momentum shift reflects strengthening internal strength after a prolonged period of weakness. 5. RSI Structure RSI shows a strong upward expansion compared to earlier sideways movement, indicating improving momentum conditions during the latest price surge. 6. Volume Behaviour The breakout candle is supported by a notable expansion in volume relative to recent weeks, highlighting increased participation during the move. 7. Overall Observation The chart reflects price rebounding strongly within a broader corrective structure, testing an important resistance zone while momentum and volume show clear improvement. 📢 Disclaimer: For educational and technical analysis purposes only; not investment advice. 👤 Rajneesh Sharma – SEBI Registered Research Analyst (INH000020332)

See More
Chahat Aggrawal

Chahat Aggrawal

12 Feb • 5:23 PM · SEBI-Registered Analyst

Lincoln Pharma Q3FY26: PAT Jumps 37.7%, Revenue Up 13%

💊

LINCOLN
reported a strong Q3FY26 performance with consolidated net profit rising 37.70% YoY to ₹28.60 crore. Revenue from operations grew 13.49% to ₹166.32 crore, driven by healthy traction across key therapeutic segments and improved operational performance.

See More
Chahat Aggrawal

Chahat Aggrawal

10 Jan • 9:00 PM · SEBI-Registered Analyst

Lincoln Pharmaceuticals Secures CRISIL A/Stable Rating

🏥 CRISIL has reaffirmed

LINCOLN
’ credit ratings, assigning CRISIL A/Stable for long-term facilities and CRISIL A1 for short-term facilities. The reaffirmation reflects the company’s strong financial profile, healthy cash flows, and stable business fundamentals.

See More
Ashish Kumar

Ashish Kumar

15 Feb • 1:27 PM · SEBI-Registered Analyst

Small-Cap Stocks Take a Hit as BSE Index Dips

The BSE Small-cap index has seen a significant decline, dropping 9.5 percent. This downturn has affected a large number of stocks, with over 450 experiencing losses between 10 and 41 percent. Several companies have been particularly hard hit, with shares falling between 25 and 41 percent. These include NGL Fine Chem,

NATCOPHARM
, Excel Industries, Orchid Pharma, WPIL, Tilaknagar Industries, Banco Products (India), Senco Gold, Suyog Telematics, Concord Biotech, Zaggle Prepaid Ocean Services,
PRINCEPIPE
Pipes & Fittings, Gensol Engineering, Lincoln Pharmaceuticals, and Suraj Estate Developers. Despite the overall negative trend, some stocks have managed to buck the trend and post gains. Among these are Garware Hi-Tech Films, Kennametal India, Godfrey Phillips India, Vimta Labs, Indo Count Industries, TCPL Packaging, and Redington. This downturn in the small-cap segment comes as the BSE Small-cap index has slipped 22% from its record high. Investors are likely keeping a close watch on market trends to assess the potential for further fluctuations.

See More
Vibhu Jain

Vibhu Jain

3 Dec • 2:40 PM · SEBI-Registered Analyst

The stock market is constantly evolving

The stock market is constantly evolving and today, the small cap segment has caught the attention of investors. According to the latest market summary, the BSE Smallcap index has seen a rise of 0.97% and in the last 5 days, it has surged by 3.01%. This makes it the best performing segment across MCaps. Among the top performers in this segment is Lincoln Pharma, with a return of 19.74%. On the other hand, C.E. Info System has been the worst performer with a return of -8.78%. This shows the volatility of the small cap market, where gains and losses can be significant. The advance decline ratio of stocks in this segment is also noteworthy, with 688 stocks advancing and 251 stocks declining. This translates to a ratio of 2.74x, indicating a positive trend in the small cap market. Investors should also take note of the recent upgrades in stock scores for some companies in this segment. Cosmo First, Gabriel India, NCC, AGI Greenpac, and Affle India have all been upgraded from Hold to Buy. This suggests that these stocks have the potential to perform well in the near future. With the small cap segment showing promising growth and potential, investors should keep a close eye on these stocks and make informed decisions to capitalize on the current market trend.

See More

Frequently Asked Questions

What is the share price of Lincoln Pharmaceuticals Ltd.?

What is the market cap of Lincoln Pharmaceuticals Ltd.?

Should I buy Lincoln Pharmaceuticals Ltd. stock now?

What is the 52 week high and low of Lincoln Pharmaceuticals Ltd.?

Is the Lincoln Pharmaceuticals Ltd. stock good to buy?

Is Lincoln Pharmaceuticals Ltd. a good buy for the long term?

Is Lincoln Pharmaceuticals Ltd. overvalued or undervalued?

What is the PE and PB ratio of Lincoln Pharmaceuticals Ltd.?

Start Now